Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS
patients. A 48-week treatment period followed by an individualized follow-up period until
normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.